- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Enrollment open, Phase classification, Metastases: A Study of Sovilnesib in Subjects with Ovarian Cancer (clinicaltrials.gov) - Apr 18, 2024
P1, N=120, Recruiting,
Compound 16 showed potential as a candidate for the clinical treatment of ovarian cancer. Not yet recruiting --> Recruiting | Phase classification: P1b --> P1
- |||||||||| GSC000190 / GeneScience
GSC000190, a highly potent inhibitor of KIF18A, for tumors with chromosome instability (Section 27) - Mar 5, 2024 - Abstract #AACR2024AACR_2693;
In an HGSOC PDX model which is resistant to platinum and olaparib, GSC000190 induced strong tumor regression both as single agent and through combination without significant body weight reduction...GSC000190 has a favorable ADME profile in rodents, dogs and NHPs, as well as a much better safety profile. GSC000190 is now under IND-enabling study and P1 study is planned in the second quarter of 2024.Legal entity responsible for the study: The authors.Disclosure: All authors have declared no conflicts of interest.
- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Trial completion, Enrollment change, Metastases: Study of AMG 650 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 9, 2023
P1, N=66, Completed,
Collectively, our results provide a rational therapeutic strategy for selective targeting of CIN cancers via AMG 650, a first-in-class KIF18A inhibitor. Active, not recruiting --> Completed | N=140 --> 66
- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Trial completion date, Trial primary completion date, Metastases: Study of AMG 650 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 24, 2022
P1, N=140, Active, not recruiting,
Trial completion date: Mar 2024 --> Feb 2023 Trial completion date: Apr 2025 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Oct 2022
- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Enrollment closed, Metastases: Study of AMG 650 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 18, 2022
P1, N=140, Active, not recruiting,
Trial completion date: Apr 2025 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Oct 2022 Recruiting --> Active, not recruiting
- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Trial primary completion date, Metastases: Study of AMG 650 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jan 27, 2022
P1, N=140, Recruiting,
AMG 650 has advanced to Phase I clinical testing in patients with advanced solid tumors that harbor TP53 genetic mutations. Trial primary completion date: Oct 2022 --> Sep 2023
- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Trial completion date, Trial primary completion date, Metastases: Study of AMG 650 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jan 14, 2021
P1, N=120, Recruiting,
The study began enrolling pts in March 2020 and is ongoing. Trial completion date: Oct 2023 --> Apr 2024 | Trial primary completion date: Jun 2022 --> Oct 2022
- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Trial completion date, Trial primary completion date, Metastases: Study of AMG 650 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Jun 18, 2020
P1, N=120, Recruiting,
Trial completion date: Oct 2023 --> Apr 2024 | Trial primary completion date: Jun 2022 --> Oct 2022 Trial completion date: Mar 2023 --> Oct 2023 | Trial primary completion date: Nov 2021 --> Jun 2022
- |||||||||| sovilnesib (AMG 650) / Volastra Therap
Enrollment open, Trial completion date, Trial primary completion date, Metastases: Study of AMG 650 in Adult Participants With Advanced Solid Tumors (clinicaltrials.gov) - Apr 8, 2020
P1, N=120, Recruiting,
Trial completion date: Mar 2023 --> Oct 2023 | Trial primary completion date: Nov 2021 --> Jun 2022 Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Mar 2023 | Trial primary completion date: Jul 2022 --> Nov 2021
|
